Predictive Biosciences gains $25m in third-round funding with repeat investors following ProQuest Investments.
Kaiser Permanente Ventures (KPV), the corporate venturing division of a US-based healthcare provider, has reinvested in cancer management company Predictive Biosciences.
Predictive raised $25m in its series C round, led by venture capital firm ProQuest Investments as a new investor. As well as KPV, all Predictive’s previous investors returned as well: Flybridge Capital Partners (known as IDG Ventures Boston until 2008 when it changed its name after bringing in outside investors as limited partners to parent media group IDG), Highland…
